7 completed, 5 unknown, 2 recruiting, 1 approved for marketing. 5 Not applicable, 5 Phase 2, 4 Phase 1, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 2, Unknown 2, Terminated 1 |
| Phase 2 | 5 | Completed 3, Unknown 2 |
| Phase 1 | 4 | Unknown 2, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Thromboangiitis Obliterans: new trials by email Literature Review of Thromboangiitis Obliterans trials Research Report on Thromboangiitis Obliterans
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease BOTOX INJECTION - Buerger Disease, Raynaud Syndrome | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 8 | 2027-01-01 | 2026-07-23 |
| A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g) - Thromboangiitis Obliterans (Buerger's Disease) | Phase 1 | Recruiting | Antidote Therapeutics, Inc | 15 | 2025-10-01 | 2025-10-15 |
| Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L) NL003, Placebo - Peripheral Arterial Disease(PAD), Arterial Occlusive Disease | Enrolling by invitation | Beijing Northland Biotech. Co., Ltd. | 542 | 2025-06-30 | 2025-07-11 | |
| Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells - Critical Limb Ischemia, Buerger's Disease | Phase 4 | Recruiting | Cell Biopeutics Resources Sdn Bhd | 3 | 2024-01-01 | 2025-09-09 |
| Subtle Energy Transmission and Tao Calligraphy Mindfulness in Telomere Length in Peripheral Blood Leukocytes Mindfulness practice with Calligraphy - Telomere Length, Quality of Life | Not applicable | Terminated | Sha Research Foundation | 12 | 2023-06-15 | 2025-04-15 |
| Autologous Fat Grafting in the Treatment of Critical Limb Ischaemia Autologous Fat Grafting - Critical Limb Ischemia, Peripheral Arterial Disease - PAD | Not applicable | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 20 | 2021-01-01 | 2021-02-10 |
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) CLBS12, SOC - Critical Limb Ischemia, Buerger Disease | Phase 2 | Completed | Lisata Therapeutics, Inc. | 33 | 2017-11-01 | 2024-10-09 |
| Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia ADRC injection, ADRC isolation, Liposuction - Critical Limb Ischemia, Arteriosclerosis Obliterans | Phase 1 / Phase 2 | Unknown | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 9 | 2016-07-01 | 2016-08-12 |
| Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia autologous purified CD34+ cells, autologous peripheral blood mononuclear cells - Thromboangiitis Obliterans, Arteritis | Not applicable | Unknown | Shanghai Zhongshan Hospital | 50 | 2014-03-01 | 2016-04-19 |
| A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease Allogeneic Mesenchymal Stem Cells - Critical Limb Ischemia, Buerger's Disease | Phase 2 | Completed | Stempeutics Research Pvt Ltd | 90 | 2012-01-01 | 2016-09-13 |
| Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia ResQ processed bone marrow sample, Ficoll conventional cell processing method - Critical Limb Ischemia, Peripheral Arterial Disease | Phase 1 / Phase 2 | Unknown | Xuanwu Hospital, Beijing | 50 | 2011-10-01 | 2011-10-12 |
| Contrast Enhanced Ultrasound and Muscle contrast echographie with hexafluorur of sulfur - Ischemia, Thromboangiitis Obliterans | Not applicable | Completed | University Hospital, Grenoble | 32 | 2011-02-01 | 2016-03-07 |
| Autologous Endothelial Progenitor Cells (EPCs) From Peripheral Blood in the Treatment of Critical Limb Ischemia Endothelial progenitor cells intramuscular implant - Critical Limb Ischemia | Phase 1 / Phase 2 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 8 | 2009-01-01 | 2012-06-14 |
| Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan Bosentan - Thromboangiitis Obliterans | Completed | Hospital Universitario Getafe | 12 | 2009-01-01 | 2016-08-16 | |
| ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's Disease Thromboangiitis Obliterans, Atheromatous Arteritis | Completed | University Hospital, Lille | 224 | 2008-09-01 | 2016-11-10 | |
| Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease RNL-Vascostem® - Buerger's Disease | Not applicable | Completed | R-Bio | 15 | 2007-12-01 | 2019-06-05 |
| TACT-NAGOYA: Therapeutic Angiogenesis Using Cell Transplantation Autologous Bone Marrow Mononuclear Cell Implantation - Buerger Disease, Arteriosclerosis Obliterans | Unknown | Nagoya University | 2003-08-01 | 2005-12-30 | ||
| Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease Selexipag - Non-healing Wound, Thromboangiitis Obliterans | Approved for marketing | Actelion | 2026-03-27 |
Chronic Limb-Threatening Ischemia (9) · Peripheral Arterial Disease (4) · Arteriosclerosis Obliterans (3) · Diabetic Foot (2) · Arterial Occlusive Diseases (1) · Arteritis (1) · Behavior, Addictive (1) · Diabetic Angiopathies (1) · Ischemia (1) · Marijuana Abuse (1) · Mental Disorders (1) · Personality Disorders (1) · Raynaud Disease (1) · Scleroderma, Systemic (1)
Cardiovascular Diseases (18) · Vasculitis (18) · Arterial Occlusive Diseases (17) · Vascular Diseases (17) · Peripheral Vascular Diseases (11) · Arteriosclerosis (10) · Atherosclerosis (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10) · Chronic Disease (9) · Disease Attributes (9) · Ischemia (9) · Peripheral Arterial Disease (6) · Diabetes Complications (3) · Diabetes Mellitus (3)
Bosentan (1) · Botulinum Toxins (1) · Cell- and Tissue-Based Therapy (1) · Lipectomy (1) · Standard of Care (1) · betibeglogene autotemcel (1) · selexipag (1)
Actelion (1) · Antidote Therapeutics, Inc (1) · Beijing Northland Biotech. Co., Ltd. (1) · Cell Biopeutics Resources Sdn Bhd (1) · Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Hospital Universitario Getafe (1) · Lisata Therapeutics, Inc. (1) · Nagoya University (1) · R-Bio (1) · Sha Research Foundation (1) · Shanghai Zhongshan Hospital (1) · Stempeutics Research Pvt Ltd (1) · University Hospital, Grenoble (1)
China (3) · France (3) · Italy (2) · Japan (2) · Canada (1) · India (1) · Malaysia (1) · Russia (1) · South Korea (1) · Spain (1) · United States (1)
Andrey A Kalinin, MD, PhD (1) · Andrey A Pulin, MD, PhD (1) · Attilio Odero, Professor (1) · Christophe Seinturier, Doctor (1) · Dr Alfred Augustine (1) · Dr Anirban Chatterjee (1) · Dr Anita Dhar (1) · Dr Murali Krishna (1) · Dr Radhakrishnan R (1) · Dr Rajiv Parakh (1) · Dr Rajkumar M (1) · Dr Sanjay Desai (1) · Dr Santanu Dutta (1) · Dr Vidyasagaran T (1)
PMID 17251666, PMID 22333218, PMID 22498564, PMID 25217217, PMID 26526721, PMID 30172703, PMID 33399273, PMID 35313967
U01DA058547 (1)